Excess body weight—including overweight and obesity—is a significant risk factor for cancer. Research from the American Cancer Society estimates that it contributes to approximately 5 percent of ...

Evaluation of the impact of lymph node ratio on survival in patients with pancreatic cancer undergoing neoadjuvant therapy. Outcomes of surveillance in patients with intraductal papillary mucinous ...

Ovarian cancer is caused by a harmful overgrowth of cells in and around the ovaries. The cancer can start in the lining of the ovary or fallopian tube, the supportive tissue, or in the egg cell. There ...

To provide updated guidance regarding neoadjuvant chemotherapy (NACT) and primary cytoreductive surgery (PCS) among patients with stage III-IV epithelial ovarian, fallopian tube, or primary peritoneal ...

While it doesn’t raise the risk for all ovarian cancer in general, it does seem to increase one’s odds of developing the subtype called mucinous ovarian cancer. Overweight or obese ...

Paihia resident Ruby Smith was diagnosed with stage III mucinous ovarian cancer only weeks after the birth of her third child and now needs immune therapy in Japan. Photo / Denise Piper The Paihia ...

mixed epithelial carcinoma, mucinous adenocarcinoma, and cervical cancer. It was also under development for solid tumors, refractory or relapsed diffuse large B-cell lymphoma, osteosarcoma, ...

When the gene testing results returned, Mrs Gard was told she tested positive for the BRCA1 gene mutation, a faulty gene that significantly increases the odds of developing ovarian cancer among ...

AI models outperform traditional statistics in predicting post-complete cytoreduction outcomes in ovarian cancer patients. AI's diagnostic accuracy was high for predicting overall survival and no ...

The American Cancer Society (ACS) today released Cancer Statistics, 2025, the organization's annual report on cancer facts and trends. The new findings show the cancer mortality rate declined by ...

Our objective was to better understand ovarian cancer metastasis and identify candidate biomarkers and drug targets for predicting and preventing ovarian cancer recurrence. Methods: Transcripts of 770 ...